Ventyx Biosciences (NASDAQ:VTYX) Sets New 1-Year High at $44.30
Ventyx Biosciences (NASDAQ:VTYX) Sets New 1-Year High at $44.30
Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $44.30 and last traded at $44.30, with a volume of 4297 shares changing hands. The stock had previously closed at $43.13.
文蒂克斯生物科学公司(纳斯达克代码：VTYX-GET评级)在周五午盘交易中创下52周新高。该公司盘中一度高见44.30美元，最新报44.30美元，成交量为4,297股。该股此前收盘价为43.13美元。
Analyst Ratings Changes
分析师评级发生变化
A number of analysts have recently commented on the stock. Evercore ISI boosted their price objective on shares of Ventyx Biosciences from $50.00 to $65.00 in a research report on Thursday, January 26th. Canaccord Genuity Group increased their price objective on shares of Ventyx Biosciences from $35.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, January 31st. Morgan Stanley started coverage on shares of Ventyx Biosciences in a report on Thursday, November 17th. They issued an "overweight" rating and a $45.00 target price for the company. The Goldman Sachs Group started coverage on shares of Ventyx Biosciences in a report on Monday, December 19th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, Oppenheimer raised their price target on shares of Ventyx Biosciences from $55.00 to $60.00 and gave the stock an "outperform" rating in a report on Friday, January 27th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $52.78.
一些分析师最近对该股发表了评论。在1月26日星期四的一份研究报告中，Evercore ISI将Ventyx Biosciences的股票目标价从50.00美元上调至65.00美元。在1月31日星期二的一份研究报告中，Canaccel Genuity Group将Ventyx Biosciences的股票目标价从35.00美元上调至54.00美元，并给予该股“买入”评级。摩根士丹利在11月17日星期四的一份报告中开始了对文迪思生物科学公司股票的报道。他们对该公司的评级为“增持”，目标价为45.00美元。高盛在12月19日星期一的一份报告中开始对文迪思生物科学的股票进行报道。他们对该公司的评级为“买入”，目标价为50美元。最后，奥本海默在1月27日(星期五)的一份报告中将Ventyx Biosciences的股票目标价从55.00美元上调至60.00美元，并给予该股“跑赢大盘”的评级。根据MarketBeat.com的数据，8位分析师对该股的评级为买入，目前该股的平均评级为“买入”，平均目标价为52.78美元。
Ventyx Biosciences Trading Up 1.8 %
Ventyx生物科学公司股价上涨1.8%
The firm has a fifty day moving average price of $33.07 and a two-hundred day moving average price of $28.57.
该公司的50日移动均线价格为33.07美元，200日移动平均价格为28.57美元。
Insiders Place Their Bets
内部人士下注
In other Ventyx Biosciences news, CEO Raju Mohan sold 276,997 shares of the company's stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $29.01, for a total value of $8,035,682.97. Following the transaction, the chief executive officer now owns 1,564,814 shares of the company's stock, valued at approximately $45,395,254.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ventyx Biosciences news, CEO Raju Mohan sold 276,997 shares of the stock in a transaction dated Friday, December 2nd. The stock was sold at an average price of $29.01, for a total value of $8,035,682.97. Following the completion of the sale, the chief executive officer now directly owns 1,564,814 shares in the company, valued at $45,395,254.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director William Richard White sold 33,353 shares of the stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $35.10, for a total value of $1,170,690.30. The disclosure for this sale can be found here. Insiders have sold a total of 1,206,646 shares of company stock valued at $36,781,043 in the last quarter. 49.10% of the stock is currently owned by insiders.
在Ventyx Biosciences的其他消息中，首席执行官拉朱·莫汉在12月2日(星期五)的一笔交易中出售了276,997股该公司股票。股票以29.01美元的平均价格出售，总价值为8,035,682.97美元。交易完成后，这位首席执行官现在拥有1,564,814股公司股票，价值约45,395,254.14美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。在Ventyx Biosciences的其他消息中，首席执行官拉朱·莫汉在12月2日星期五的交易中出售了276,997股该股。股票以29.01美元的平均价格出售，总价值为8,035,682.97美元。出售完成后，首席执行官现在直接拥有公司1,564,814股，价值45,395,254.14美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在以下网址获得这个环节。此外，董事威廉·理查德·怀特在1月23日(星期一)的交易中出售了33,353股该股。这些股票的平均价格为35.10美元，总价值为1,170,690.30美元。关于这次销售的披露可以找到这里。上个季度，内部人士总共出售了1,206,646股公司股票，价值36,781,043美元。49.10%的股份目前由内部人士持有。
Hedge Funds Weigh In On Ventyx Biosciences
对冲基金参与Ventyx Biosciences
Several hedge funds and other institutional investors have recently made changes to their positions in VTYX. Birchview Capital LP grew its stake in shares of Ventyx Biosciences by 36.4% in the third quarter. Birchview Capital LP now owns 45,000 shares of the company's stock valued at $1,571,000 after buying an additional 12,000 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $4,072,000. TD Asset Management Inc. purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $570,000. The Manufacturers Life Insurance Company purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $980,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Ventyx Biosciences in the 3rd quarter valued at about $132,000. Hedge funds and other institutional investors own 95.57% of the company's stock.
几家对冲基金和其他机构投资者最近改变了他们在VTYX的头寸。Birchview Capital LP在第三季度增持了Ventyx Biosciences的股份36.4%。Birchview Capital LP现在拥有45,000股该公司股票，价值1,571,000美元，上个季度又购买了12,000股。Nantahala Capital Management LLC在第三季度购买了Ventyx Biosciences的新股份，价值约4,072,000美元。TD Asset Management Inc.在第三季度购买了Ventyx Biosciences价值约57万美元的新股份。制造商人寿保险公司在第三季度购买了文蒂克斯生物科学公司的新股份，价值约98万美元。最后，SG America Securities LLC在第三季度购买了Ventyx Biosciences的新股份，价值约13.2万美元。对冲基金和其他机构投资者持有该公司95.57%的股票。
Ventyx Biosciences Company Profile
Ventyx生物科学公司简介
(Get Rating)
(获取评级)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
文蒂克斯生物科学公司是一家临床阶段的生物制药公司，开发用于治疗一系列炎症性疾病的小分子候选产品。它的主要临床候选产品是VTX958，这是一种治疗牛皮癣、牛皮癣关节炎和克罗恩病的选择性变构酪氨酸激酶2型抑制剂。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免费获取StockNews.com关于Ventyx生物科学的研究报告(VTYX)
- 市场回顾周-1/30-2/3
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ventyx生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ventyx Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。